-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Dusting Vs. Basketing: Strategies for Disintegrating Renal Stones
Dusting, a new protocol for treating kidney stones using recent laser technologies, has proven to deliver successful patient outcomes equal to those of traditional basketing, according to a study by the Endourology Disease Group for Excellence.
-
Featured
Benefits of Cytoreductive Nephrectomy with Targeted Cancer Therapy for Metastatic Renal Cell Cancer
Since the advent of targeted cancer therapies in the mid-2000s, there has been a dramatic reduction in cytoreductive nephrectomies. Dr. Michael Blute of Massachusetts General Hospital states that the reduction is concerning, since cytoreductive nephrectomy can provide a strong survival advantage to patients with metastatic disease.
-
Allopurinol Treatment-to-Target Does Not Increase Mortality Risk in Patients With Comorbid Gout, CKD
Yuqing Zhang, DSc, Hyon K. Choi, MD, and colleagues found that allopurinol use does not increase the five-year risk of death in patients with gout and concurrent chronic kidney disease, either overall or when analyses were limited to patients who achieved the target serum urate level or required dose escalation.
-
Acute MI Survivors with Kidney Failure Have Increased Risk of HF Hospitalization
Srikanth Yandrapalli, MD, a clinical and research fellow in Interventional Cardiology, and colleagues determined that survivors of acute myocardial infarction with either acute or chronic kidney failure have 52%–99% greater odds of hospitalization for heart failure within six months than those without kidney disease.
-
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
Mitomycin chemoablation with a mitomycin gel, a novel treatment offered in the Department of Urology at Massachusetts General Hospital, can avoid the need for surgical removal of the kidney and ureter in patients with upper tract urothelial cancer.
Kidney Contributors
-
Brian Howard Eisner, MD
Co-Director, Kidney Stone Program, Assistant Professor of Surgery, Harvard Medical School
Recent Article
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
-
-
Michael G. Fitzsimons, MD
Interim Director, Division of Cardiac Anesthesia, CABG Redesign Committee, CABG Redesign Pre-op Subcommittee chair
Recent Article
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach -
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
-
Mukesh G. Harisinghani, MD
Director, Abdominal MRI, Department of Radiology, Massachusetts General Hospital
Recent Article
Review: Advances in Radiologic Staging of Colorectal Cancer
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.